// App-Quantinova.ai

TPS4664 : A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.

Researchers

Presenter

  • Esther Pijnappel

Principal Investigators

  • Judith de Vos-Geelen

  • Teresa Macarulla Mercade

  • Davide Melisi

  • Per Pfeiffer

  • Gerald W. Prager

  • Hanneke W.M. Van Laarhoven

  • Johanna Wilmink

Medical Centers

  • Amsterdam UMC Location AMC, Amsterdam, Netherlands

  • Maastricht University Medical Center, Maastricht, Netherlands

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Digestive Molecular Clinical Oncology, University of Verona, Verona, Italy

  • Department of Oncology, Odense University Hospital, Odense, Denmark

  • Medical University of Vienna, Vienna, Austria

  • Amsterdam UMC, University of Amsterdam, Department of Surgery, Cancer Center Amsterdam, Amsterdam, Netherlands

  • Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands

Locations

  • Netherlands

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Irinotecan

  • Adrucil injection

  • Fluorouracil

  • Gemcitabine

Outcome

  • N/A

Study Design

  • Randomized

  • Fixed Dose

  • Open Label

  • Multicenteric

Phase

  • NA

Study Id's

  • NCT03986294

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved